Pfizer’s Revatio flunks paediatric hypertension study

Gottlieb joins Pfizer board, a few weeks after quitting FDA

Former FDA commissioner Scott Gottlieb has stoked controversy after being appointed to Pfizer’s board of directors, just a few weeks after leaving his government post.

As Lyrica patent expiry looms, Pfizer buys Array for $11.4bn

Pfizer has a made a $48 per share play for Array Biopharma, which values the cancer specialist at $11.4 billion.

Pfizer’s Lyrica fails phase 3 trial in epilepsy

Pfizer’s Lyrica has failed to meet its primary endpoint in a phase 3 trial in primary generalised tonic-clonic (PGTC) seizures.

EU regulators slap safety restriction on Pfizer's Xeljanz

European safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher dose in some patients with ulcerative colitis because of concerns of incr

Pfizer selects first GPCR candidate from Sosei Heptares tie-...

Pfizer has selected the first drug candidate from a collaboration with Sosei Group to develop drugs for major diseases, which are aimed at targets from the G protein-coupled receptor (GPCR)